Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor
Immutep Limited (ASX: IMM, NASDAQ: IMMP) said the USPTO granted US patent 12,673,088 covering methods to treat cancer using eftilagimod alfa with anti-PD-1 or anti-PD-L1 antibodies. The patent expires 20 Jan 2036 and is the fourth US patent in the series, following earlier grants from 2020, 2021 and 2023.
How this was made
The 30-second read
Why it matters
The USPTO grant expands and extends Immutep’s US intellectual property protection for Efti in combination with anti-PD-1 or anti-PD-L1 antibodies, with an expiry date of 20 Jan 2036.
Market read
A concrete IP milestone for Efti PD-1 combination regimens, supportive for defensibility and business development optionality, but not tied to new clinical or regulatory outcomes.
What to watch
Traders may want to monitor whether the patent scope meaningfully covers current or planned clinical combinations, and whether any competitor challenges or design-arounds are likely.
Background
The release states this is the fourth US patent in a series for eftilagimod alfa combination methods with PD-1 pathway inhibitors, following earlier parent/divisional grants.
Ticker impact
Immutep announced USPTO grant of a fourth US patent covering eftilagimod alfa combined with anti-PD-1 or anti-PD-L1 antibodies, expiring 2036.
Modest positive bias, mainly supportive for longer-dated valuation and partnership optionality rather than near-term earnings.
The news is a concrete regulatory/IP milestone (new granted patent) but it does not include clinical readouts, approvals, or financial guidance that would likely drive a large immediate repricing.
Market effects
Reinforces the value of combination-therapy IP in immuno-oncology, potentially improving perceived defensibility for LAG-3 agonist platforms.
Limited, mostly relevant to US-listed biotech sentiment and Immutep’s shareholder base.
US patent coverage can matter for global commercialization and partnering discussions, but the article provides no new international filings or deals.
Counterpoint
A granted patent does not guarantee clinical or commercial success; without new efficacy/safety data, the market may discount the impact.
Key entities
- companyImmutep Limited
Clinical-stage biotech developing LAG-3 related immunotherapies, including eftilagimod alfa (Efti).
- drug_candidateEftilagimod alfa (Efti)
MHC class II agonist immunotherapy under evaluation in multiple solid tumor indications.
- regulatorUSPTO
Granted the new US patent (12,673,088) covering combination treatment methods.
